Transplant Research and Risk Management最新文献

{"title":"Hyperosmolar nonketotic hyperglycemic coma induced by methylprednisolone pulse therapy for acute rejection after liver transplantation: A case report and review of the literature","authors":"Jian Zhou, W. Ju, Xiao-Peng Yuan, Xiao-feng Zhu, Dongping Wang, Xiaoshun He","doi":"10.2147/TRRM.S69516","DOIUrl":"https://doi.org/10.2147/TRRM.S69516","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 23–26 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"23-26"},"PeriodicalIF":0.9,"publicationDate":"2014-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S69516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac allograft immune activation: current perspectives","authors":"D. Chang, J. Kobashigawa","doi":"10.2147/TRRM.S71055","DOIUrl":"https://doi.org/10.2147/TRRM.S71055","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2015:7 13–22 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"13-22"},"PeriodicalIF":0.9,"publicationDate":"2014-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S71055","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizational determinants in the procurement and transplantation pathway: a review","authors":"M. Triassi, E. Giancotti, A. Nardone, G. Mancini, F. Rubba","doi":"10.2147/TRRM.S67467","DOIUrl":"https://doi.org/10.2147/TRRM.S67467","url":null,"abstract":"s were screened. In the next phase, the full text of all abstracts considered potentially relevant by at least one of the reviewers was evaluated. Inconsistencies in decision-making within this second phase were solved based on consensus between both reviewers. In this phase, for every study we defined whether the organization was considered relevant and what the scenario was. The information was extracted from each study based on bibliographic details (author, journal, year of publication, and language). As many as 1,071 studies were analyzed, and 81 were selected as potentially relevant. Results: We found three prevalent areas of interest focused on organizational elements: global organizational strategies scenario, clinical hospital organization, and citizenship and social scenario. Conclusion: We reached the conclusion that organization has a central role in different scenarios of procurement and transplantation in a continuum from government to hospital (the core of the system) and finally among citizens. A standardized hospital pathway definitely remains the essential step in order to ameliorate either procurement or transplantation.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"7 1","pages":"1-12"},"PeriodicalIF":0.9,"publicationDate":"2014-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S67467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68497058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplant coronary heart disease: challenges and solutions","authors":"J. Jentzer, G. Hickey, S. Khandhar","doi":"10.2147/TRRM.S50846","DOIUrl":"https://doi.org/10.2147/TRRM.S50846","url":null,"abstract":"© 2014 Jentzer et al. Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure after heart transplantation. A variety of causes, including donor heart characteristics, recipient risk factors, and immune-mediated influences, are associated with developing CAV. In this review, we will focus on the pathophysiology of developing CAV and various methods to screen for this condition. The pathogenesis of CAV likely involves repeated injuries to the endothelium from a variety of factors such as cellular-mediated rejection, and alloimmune factors, including antibody-mediated injury, ischemia-reperfusion injury at time of transplant, cytomegalovirus infections, immunosuppression medications, systemic inflammation, and tra­ditional atherosclerosis risk factors. Patients with significant CAV are often asymptomatic, and therefore early detection by routine screening prior to graft dysfunction is crucial. There are a variety of invasive, noninvasive, and blood tests that have been studied as screening methods, and we will discuss the role of each of these in this review article. Although some treatment regimens have been established for CAV, this is an area where further studies and research are necessary.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"117-127"},"PeriodicalIF":0.9,"publicationDate":"2014-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50846","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspectives on antibody-mediated rejection after lung transplantation","authors":"C. Witt, R. Hachem","doi":"10.2147/TRRM.S50799","DOIUrl":"https://doi.org/10.2147/TRRM.S50799","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 109–115 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"34 1","pages":"109-115"},"PeriodicalIF":0.9,"publicationDate":"2014-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplantation in highly HLA-sensitized patients: challenges and solutions","authors":"Irene K Kim, A. Vo, S. Jordan","doi":"10.2147/TRRM.S50793","DOIUrl":"https://doi.org/10.2147/TRRM.S50793","url":null,"abstract":"Despite better understanding of the impact of development of the human leukocyte antigen (HLA) antibody and numerous advancements in immunosuppressive therapy, the abil- ity to successfully transplant highly sensitized patients remains a significant challenge. As the percentage of the waiting list becomes increasingly populated with highly sensitized patients, there is a growing demand for effective strategies to manage these patients. Over the past 20 years, desensitization therapies have been modified and developed, and are mainly utilized at transplant centers that have developed expertise. In addition, recognition that the highly sensitized patient population is disadvantaged on the transplant waiting list has led to recent changes in national kidney allocation policy. Furthermore, creative strategies, such as enroll- ment of sensitized patients into paired kidney exchange programs, have been developed to find compatible matches for these patients. The goal of this article is to address some of the specific challenges related to transplanting the highly sensitized patient at a high-volume transplant center with experience in desensitization and to review established and emerging solutions to help this patient population.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"99-107"},"PeriodicalIF":0.9,"publicationDate":"2014-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50793","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic lung allograft dysfunction following lung transplantation: challenges and solutions","authors":"B. Bemiss, C. Witt","doi":"10.2147/TRRM.S50896","DOIUrl":"https://doi.org/10.2147/TRRM.S50896","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 87–97 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"2014 1","pages":"87-97"},"PeriodicalIF":0.9,"publicationDate":"2014-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50896","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential for clinical pancreatic islet xenotransplantation","authors":"R. Bottino, S. Nagaraju, V. Satyananda, H. Hara, M. Wijkstrom, M. Trucco, D. Cooper","doi":"10.2147/TRRM.S50850","DOIUrl":"https://doi.org/10.2147/TRRM.S50850","url":null,"abstract":"© 2014 Bottino et al. Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated successfully by islet allotransplantation, the results of which are steadily improving. However, the number of islets that can be obtained from deceased human donors will never be sufficient to cure more than a very small percentage of patients who might benefit from transplantation. Although there are some differences in glucose metabolism between pigs and humans, the use of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly control glucose levels. Transplantation of islets into the portal vein results in islets residing in the liver; however, an early inflammatory response and rejection remain problematic, even when the recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsulation techniques provide islets with a physical barrier that prevents antibodies binding to the islet graft while still allowing insulin to be released into the recipient’s circulation; in theory, patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic structure of pigs closer to that of humans, and providing protection from the human immune response. Islet transplantation from genetically engineered pigs has been followed by insulin independence in a small number of nonhuman primates for greater than 1 year. Neonatal islets have some advantages over adult islets in that they are easier to isolate and culture, and have the ability to proliferate during the first few months after transplantation. In 2009, the International Xenotransplantation Association set up a group to encourage and advise on clinical trials of pig islet xenotransplantation; this group’s guidelines are discussed. Clinical trials of encapsulated pig islets are already under way.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"35 2 1","pages":"79-86"},"PeriodicalIF":0.9,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S50850","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple antiviral therapy with telaprevir after liver transplantation: a case series","authors":"J. Knapstein, D. Grimm, M. Wörns, P. Galle, H. Lang, T. Zimmermann","doi":"10.2147/TRRM.S65651","DOIUrl":"https://doi.org/10.2147/TRRM.S65651","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 73–78 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"73-78"},"PeriodicalIF":0.9,"publicationDate":"2014-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S65651","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68496986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus","authors":"M. Reschen, C. O'Callaghan","doi":"10.2147/TRRM.S41381","DOIUrl":"https://doi.org/10.2147/TRRM.S41381","url":null,"abstract":"(unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Transplant Research and Risk Management 2014:6 55–72 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"6 1","pages":"55-72"},"PeriodicalIF":0.9,"publicationDate":"2014-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S41381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68495543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}